Gi Dynamics

About the author:

Author name:

By Scott Power

Job title:

Senior Analyst

Date posted:

06 September 2013, 3:11 PM

Sectors Covered:

Healthcare, Life Sciences

Gi Dynamics (GID) could potentially benefit from the growing global problem of diabetes and obesity with its proprietary EndoBarrier device.

The EndoBarrier is a non-surgically implanted gastrointestinal liner which is approved for sale in Europe, South America and Australia. Major shareholders include Medtronic (12%) and J&J (12%) which add to the corporate appeal.

A capital raising was recently held to help fund a US clinical trial. Access to this significant market is expected in 2017.

I rate GID as a stock to buy, with a target price of A$1.85.

If you are interested in Gi Dynamics (GID), please contact your nearest Morgans office.

Disclaimer: Analyst owns shares

Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.